Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma Clinical Trial

Official title: Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Status Not yet recruiting

Clinical Trial Summary

To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy.

The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

• NCT number: NCT05834543
• Study type: Interventional
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: May 2023
• Completion date: December 2024